September 17, 2018 09:05 PM IST
John Porter, chief business officer at brokerage Renaissance Capital, told Reuters interest came from local and international investors.
September 11, 2018 09:50 PM IST
Commenting on the development, Cipla South Africa CEO Paul Miller said DTG is considered a best-in-class medicine providing many clinical benefits for people living with HIV.
August 13, 2018 04:20 PM IST
Centrum is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 750 in its research report dated August 09, 2018.
August 11, 2018 11:13 AM IST
Capecitabine tablets are indicated in patients with colon cancer and for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
August 09, 2018 11:22 AM IST
Drug major Cipla yesterday posted a 10 per cent increase in its consolidated net profit to Rs 451 crore for the first quarter ended June 30, driven by robust sales across various markets.
August 08, 2018 10:19 AM IST
The analysts polled by Reuters estimated the company's revenue to rise 18.21% on year to Rs 4,057.4 crore for the quarter
August 07, 2018 10:38 AM IST
Citing IQVIA data, the company said Voltaren Gel and its generic equivalents had US sales of approximately $353 million for the 12 month period ending June 2018.
July 18, 2018 02:10 PM IST
Net Sales are expected to increase by 9.5 percent Y-o-Y (up 4.4 percent Q-o-Q) to Rs. 3,859.1 crore, according to Kotak.
July 12, 2018 12:00 PM IST
The transaction required approval by the South African Competition Commission and is expected to be completed before September 30, 2018.
June 21, 2018 03:34 PM IST
The company has received final approval for its abbreviated new drug application (ANDA) for Testosterone Cypionate injection in the strengths of 100mg/ml and 200mg/ml from the US Food and Drug Administration (USFDA), Cipla said in a filing to BSE.
June 19, 2018 07:05 PM IST
The Mumbai-based firm has received final nod from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Efavirenz tablets in 600mg strength, Cipla said in a statement.
June 16, 2018 12:32 PM IST
Going forward, it expects the Sensex EPS to be Rs 1,870 for FY19 and Rs 2,241 for FY20, an increase of 36 and 20 percent, respectively.
June 14, 2018 11:32 AM IST
The company has received final approval from the United States Food and Drug Administration (USFDA) for its product which is a generic version of Hospira Inc's Isuprel injection, Cipla said in a statement.
June 08, 2018 02:15 PM IST
Cipla expects to start commercialising Basaglar in India by end of this year.
May 31, 2018 03:54 PM IST
Dolat Capital recommended accumulate rating on Cipla with a target price of Rs 585 in its research report dated May 22, 2018.
May 30, 2018 05:30 PM IST
ICICI Direct recommended hold rating on Cipla with a target price of Rs 530 in its research report dated May 23, 2018.
May 28, 2018 05:34 PM IST
JM Financial is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 600 in its research report dated May 23, 2018.
May 28, 2018 05:31 PM IST
JM Financial is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1440 in its research report dated May 23, 2018.
May 25, 2018 04:28 PM IST
KR Choksey recommended accumulate rating on Cipla with a target price of Rs 607 in its research report dated May 23, 2018.
May 23, 2018 10:33 AM IST
Brokerage houses remained positive on the stock, but slashed target prices following cut in earnings estimates.
May 22, 2018 04:28 PM IST
The operating profit margin expanded 100 basis points to 15.1 percent in Q4 from 14.1 percent in Q4FY17.
May 22, 2018 01:19 PM IST
Cipla is likely to report a net profit of Rs 356.7 crore in the fourth quarter of FY18, according to estimates of Reuters poll of analysts.
May 18, 2018 02:14 PM IST
"Under this agreement, Cipla will get exclusive marketing rights for five years in India for critical limb ischemia due to atherosclerotic peripheral arterial disease (CLI-PAD) with Stempeutics manufacturing and supplying the product to Cipla," the company said in a statement.
May 11, 2018 09:14 AM IST
“Failing to breakout 10,780 may push the Nifty into consolidation,” said Jaydeb Dey, Technical Analyst at Stewart & Mackertich Wealth Management
May 09, 2018 08:35 PM IST
Under the agreement, Cipla is responsible for obtaining regulatory approvals to distribute Afrezza in India, including approval from the Drug Controller General of India (DCGI), while MannKind will manufacture and supply the drug
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
